Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial - 24/03/22

Ikaro Breder ^a, Vaneza Lira W. Wolf ^a, Alexandre A.S. Soares ^a, Luiz Sergio F. de Carvalho ^a, Sheila T. Kimura-Medorima ^a, Riobaldo M. Cintra ^a, Joaquim Barreto ^a, Daniel B. Munhoz ^a, Jessica S. Cunha ^b, Isabella Bonilha ^a, Otavio R. Coelho-Filho ^c, Thiago Quinaglia ^a, Wilson Nadruz ^c, Gil Guerra-Junior ^d, Elza Muscelli ^c, Andrei C. Sposito ^{a, c, ⁎}
on behalf of

ADDENDA-BHS2 Trial Investigators

^a Laboratory of Vascular Biology and Atherosclerosis. University of Campinas, Campinas, SP, Brazil 

^b College of Nursing, University of Campinas, Campinas, SP, Brazil 

^c Department of Internal Medicine, University of Campinas, SP, Brazil 

^d Growth and Development Lab, Centre for Investigation in Paediatrics, University of Campinas, Campinas, SP, Brazil 

^⁎Corresponding author at: Laboratory of atherosclerosis and vascular biology (AteroLab) Cardiology Department, State University of Campinas (Unicamp). 13084-971, Campinas, SP, Brazil.Laboratory of atherosclerosis and vascular biology (AteroLab) Cardiology DepartmentState University of Campinas (Unicamp)CampinasSP13084-971Brazil

Le texte complet de cet article est disponible en PDF.